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Abstract
Background: The 5-HT3 receptor is a member of a neurotransmitter-gated ion channel family
which includes nicotinic acetylcholine, GABAA, and glycine receptors. While antibodies specific for
the 5-HT3A receptor subunit are plentiful, and have revealed a wealth of structural and functional
information, few antisera exist for the detection of 5-HT3B receptor subunits. Here we describe
the generation and characterisation of a rabbit polyclonal antiserum that specifically recognises 5-
HT3B receptor subunits
Results: Immunization of a rabbit with a 20-mer peptide, corresponding to the N-terminus of the
human 5-HT3B receptor subunit, generated serum with polyclonal antibodies from which an IgG
fraction was purified, yielding pAb77. The antibodies were shown to label 5-HT3B receptor subunits
in transfected human embryonic kidney cells and rodent tissues using Western blots.
Immunocytochemistry using pAb77 on these cells showed that 5-HT3B receptor subunits do not
reach the plasma membrane in the absence of 5-HT3A receptor subunits. Immunohistochemical
analysis of rat brain sections showed pAb77 immunoreactivity in distinct populations of cells in the
hippocampus.
Conclusion: We have demonstrated that pAb77 antibodies specifically label native and
recombinant 5-HT3B receptor subunits with high affinity and specificity. The antibody was shown
to be useful for the determination of both receptor trafficking and also mapping 5-HT3B receptor
subunit expression in the CNS.
Background
The 5-HT3 receptor is a pentameric neurotransmitter gated
ion channel that acts as a molecular switch at synapses [1].
5-HT3 receptor antagonists are used clinically for the pre-
vention of emesis, and may be useful in the treatment of
irritable bowel syndrome and alcoholism [2]. Interest-
ingly, mice lacking the 5-HT3A receptor subunit were
recently shown to possess an anxiolytic phenotype [3],
although therapeutic potential in humans appears limited
[4].
Five 5-HT3 receptor subunits have been cloned to date [5-
7], although only two (5-HT3A and 5-HT3B) have been
shown to exist in functional receptors. Homomeric 5-
HT3A receptors are notable for their sub-pS single channel
conductance [8], but co-expression with 5-HT3B receptor
subunits increases the conductance to more than 20 pS
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tamer are largely unchanged compared with the homo-
pentamer [10,11], although the Ca2+ permeability of the
heteropentamer may be ablated [12] and recovery from
desensitization quickened [13]. Additionally, rodent 5-
HT3A/B heteromers have reduced sensitivity to picrotoxin
[14], and channel gating enhancement by some anaes-
thetics (especially halothane and chloroform) is markedly
attenuated [15]. The stoichiometry of recombinant 5-
HT3A/B heteropentamers has recently been determined as
BBABA [16] but the stoichiometry of native 5-HT3 recep-
tors remains to be confirmed.
While expression of 5-HT3B receptor subunits has been
demonstrated in the peripheral nervous system [17], con-
troversy remains over their presence in the central nervous
system (CNS) [18]. In particular, an antiserum previously
generated which recognizes 5-HT3B receptor subunits
(AP86/3, [19]) labelled cells in the rat hippocampus,
despite in situ hybridisation and RT-PCR data suggesting
absence of the subunit [20,21]). On the other hand, 5-HT3
receptor expression in the brain is widespread [22] and 5-
HT3B receptor subunit mRNA has been detected in whole
brain lysates [6]. It is possible that the 5-HT3B receptor
subunit, if expressed in the brain, could be targeted to
small, discrete populations of cells. The availability of sen-
sitive and selective antisera could help to clarify these
points.
Here we describe the generation, purification and charac-
terization of polyclonal antibodies (pAb77) to a peptide
corresponding to a region of the extracellular domain of
the 5-HT3B receptor subunit.
Results and discussion
Immunoreactivity of antisera for 5-HT3B receptor subunits
Two rabbits (numbered 6376 and 6377) were immunised
with coupled peptide every two weeks for a period of
approximately two months. Test-bleeds were taken 7–10
days after immunisations. Western blots were used to test
each antiserum by probing membranes electroblotted
with separated crude lysates of human embryonic kidney
(HEK)293 cells stably expressing the human 5-HT3B recep-
tor subunit (not shown). No consistent immunoreactivity
was observed for sera from rabbit 6376 or pre-immune
serum from either animal. At week 7 and subsequent
bleeds, serum from Rabbit 6377 showed a consistent
strong immunoreactivity for a 55–60 kDa protein. The
predicted molecular weight of human 5-HT3B receptor
subunits without post-translational modifications is 50.3
kDa. We inferred that this immunoreactivity represented
labelling of the 5-HT3B receptor subunit.
Serum 6377 was tested at several different dilutions
against homogenates of HEK293 cells stably expressing 5-
HT3 receptor subunits. Western blots revealed non-spe-
cific labelling of several bands at a dilution of 1:100 of
6377 serum (not shown), but dilutions of 1:2,000 to
1:5,000 labelled a single protein band at 55–60 kDa from
lysates of cells expressing either human or mouse 5-HT3B
receptorsubunits (Figure 1). No labelling was seen with
lysates of untransfected cells, with cells expressing 5-HT3A
receptor subunits, or following pre-incubation of 6377
serum for 15 min with 5 mg/ml of the synthetic peptide
(data not shown).
Purified IgG fraction (pAb77) was tested by Western blot
for its ability to recognise 5-HT3B receptor subunit protein
as above. Purified IgG was compared with crude 6377
serum by applying each solution separately as the primary
antibody (dilution 1:1000) to nitrocellulose membranes
blotted with lysates of HEK293 cells expressing 5-HT3A or
5-HT3B receptor subunits, untransfected cells, and lysates
of N1E-115 cells (Figure 1). In common with the crude
serum, pAb77 did not label proteins from untransfected
cells or those expressing 5-HT3A receptor subunits. pAb77
IgG was shown to retain its capacity to specifically label a
55–60 kDa protein in cells expressing human 5-HT3B
receptor subunits, with a substantial decrease in non-spe-
cific background labelling.
We infer that the pAb77 antibodies are both specific and
sensitive for 5-HT3B receptor subunits. The previously
reported 5-HT3B specific antiserum, AP86/3 [19], detected
a band of 50–60 KDa at a concentration of 0.14 µg/ml.
Our new antiserum appears equally or perhaps more sen-
sitive: We observed labelling at dilutions of 1: 10,000
crude sera (~0.1 µg/ml), with strong bands using 1:5000
pAb77 (~0.2 µg/ml). This latter allowed detection of 5-
HT3B receptor subunits in homogenates of N1E-115 cells,
which express heteromeric rodent 5-HT3 receptors [23].
Here pAb77 recognised a 55–60 kDa protein, correspond-
ing to the 5-HT3B receptor subunit.
Visualisation of 5-HT3B receptor subunits by indirect 
immunofluorescence
HEK293 cells were transiently transfected with 5-HT3A or
5-HT3B receptor subunits alone or in combination, and
labelled with either pre-immune serum or final bleed pol-
yclonal serum from rabbit 6377. Typical data is shown in
Figure 2. No labelling was observed with pre-immune
serum from rabbit 6377 (Fig. 2a). Strong labelling was
obtained from permeabilized cells expressing either 5-
HT3B receptor subunits alone (Fig. 2b) or in combination
with 5-HT3A receptor subunits (Fig. 2c). Labelling was also
seen around the cell membrane of some non-permeabi-
lised cells transfected with both 5-HT3A and 5-HT3B recep-
tor subunits (Fig. 2c, right panel). This suggests that at
least some 5-HT3B receptor subunits are expressed on the
surface in the presence of 5-HT3A receptor subunits,Page 2 of 8
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remain intracellular. The presence of 5-HT3A receptor sub-
units on the surface of cells transfected with both 5-HT3A
and 5-HT3B receptor subunits was verified by labelling
with pAb120, an antisera selective for 5-HT3A receptor
subunits [24] (Figure 2d).
The extracellular location of the antisera binding site
means that it can be used to probe the location of 5-HT3B
receptor subunits on the cell membrane. Both 6377 serum
and pAb77 IgG were found to produce specific labelling
of human 5-HT3B receptor subunits expressed in permea-
bilised HEK293 cells, with low background labelling. Spe-
cific labelling of non-permeabilised cells, however, was
only seen in the presence of 5-HT3A receptor subunits (Fig.
2c), suggesting that these are required for efficient expres-
sion of 5-HT3B receptor subunits on the surface. Thus our
immunofluorescence data concur with previous reports
that 5-HT3B receptor subunits remain intracellular unless
co-expressed with 5-HT3A [29,26].
As the peptide used to generate the polyclonal antibodies
corresponds to part of the N-terminal region of the 5-HT3B
receptor subunit, it corresponds to part of the extracellular
domain. Using the recently published structure of the
homologous nicotinic acetylcholine receptor [25], we can
identify the likely region to which it binds (Fig 3). The
peptide used as an immunogen in this study corresponds
to the α-helix at the tip of the extracellular domain. This
model also reveals why pAb77 may be more sensitive than
AP86/3 in non-denaturing immunostaining experiments,
as the region against which the latter was raised appears to
be partly buried in the folded subunit.
Immunohistochemical localisation of 5-HT3B subunits in 
rat brain
The immunogenic peptide from human 5-HT3B receptor
subunits used in this study is 58% identical to the mouse
5-HT3B sequence in that region, and for 89% of the resi-
dues the charge and polarity are conserved. The sequences
of the cloned 5-HT3B receptor subunits from mouse and
rat in the region of the peptide used in this study are iden-
tical [23]. Western blots of HEK293 cells transfected with
mouse 5-HT3B receptor subunits or mouse brain (but not
liver) homogenates (Figure 1) showed that the polyclonal
antibodies specifically labelled a band of approximately
55–60 kDa corresponding to 5-HT3B receptor subunits. A
further band, of Mr approximately 35 kDa was detected by
pAb77 in mouse brain or N1E-115 cell homogenates. An
extra 35 kDa band has previously been observed with pol-
yclonal antibodies raised against the 5-HT3A receptor sub-
unit, and considered to represent a degradation product
[24], although differing glycosylation state or a splice var-
iant are also possibilities.
The antibodies were used in further immunohistochemi-
cal experiments to determine the distribution of 5-HT3B
receptor subunits in rat brain and thereby expand the
mapping of 5-HT3A receptors previously described [27].
Sections of rat hippocampus were probed with either final
bleed serum from rabbit 6377 or pAb77, and the optimal
dilution was determined to be 1:1,000–1:5,000. The pat-
tern of labelling was not significantly different between
crude 6377 serum and purified pAb77. The data show a
general light labelling of neurons plus a stronger staining
of certain cells in the pyramidal and molecular layers of
the hippocampus (Figure 4).
Similar results were obtained with pAb77 in rat hippoc-
ampus as were previously demonstrated for the 5-HT3A
specific antibody, pAb120, generated in a previous study
[24], except that no axonal labelling was seen with pAb77.
The lack of axonal labelling by pAb77 could reflect a dif-
ference in the sub-cellular distribution of the subunits,
although further experiments are required to confirm this.
In situ hybridisation using riboprobes has revealed that
different cell types in the rat spinal cord can express differ-
ent combinations of 5-HT3 receptor subunits. 70% of cells
in the rat spinal cord express 5-HT3A receptor subunits, but
only 50% of those express 5-HT3B receptor subunits, while
91% of neurons that express 5-HT3B receptor subunits also
express 5-HT3A [28]. Additionally, it has been shown that
differentiation of rat PC-12 cells induced by NGF
increases 5-HT3B receptor subunit expression [23]. Our
data, and that utilizing AP86/3 serum [19], which also
produced labelling of rat hippocampal sections, support
the presence of 5-HT3B receptor subunits on certain CNS
neurons, and suggests that 5-HT3B receptor subunits are
present at low concentrations and are highly localised in
discrete populations. The presence of the 5-HT3B receptor
subunit in the CNS may in fact be neuroprotective, as het-
eropentameric 5-HT3 receptors have a very low Ca2+ per-
meability relative to homopentameric 5-HT3A receptors,
which precludes the possibility of Ca2+-induced neurotox-
icity in the CNS being due to 5-HT3A/B heteropentameric
receptors [12].
Conclusion
Polyclonal antiserum raised against the peptide,
27PQDSALYHLSKQLLQKYHK46C, was shown to specifi-
cally bind 5-HT3B receptor subunits with high affinity,
allowing the labelling of human and rodent 5-HT3B recep-
tor subunit protein in Western blot, immunocytochemi-
cal and immunohistochemical procedures. It was found
that the majority of 5-HT3B receptor subunits, when
expressed alone, do not reach the cell surface, but that co-
expression of 5-HT3A with 5-HT3B receptor subunits per-
mits expression of 5-HT3B receptor subunits in the plasma
membrane, as reported previously [29]. Receptor subunits
were observed in rat hippocampal slices, but only in aPage 3 of 8
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in low abundance and may be highly localised. This new
pAb77 antiserum should help to clarify the location and
function of both native and recombinant 5-HT3B receptor
subunits.
Methods
Design and synthesis of antigenic peptide
The peptide sequence of the human 5-HT3B receptor sub-
unit was analysed with ANTHEPROT v5.2, [30] and
regions of the protein predicted to have a high probability
of antigenicity were identified. A second program, ANTI-
GENIC, from the EMBOSS molecular biology software
suite was used to determine candidate peptides [31]. As
very short peptides may decrease antigenicity, candidates
of less than thirteen residues were discarded. Peptides
with more than fifteen amino acids could increase the
chance of antibodies being generated against more than
one area of charge density [32] therefore these were also
discarded. Candidates not in the predicted N-terminal
domain were eliminated to allow extracellular labelling
by the antibody. The final choice of the peptide
27PQDSALYHLSKQLLQKYHK46C, was made because it
contains a high proportion of charged residues and is in a
similar region just C-terminal to the signal peptide to the
peptide that was previously used successfully to generate
antibodies selective for the 5-HT3A receptor subunit [24].
The final cysteine residue was added to the sequence to
allow coupling to the carrier. The peptide sequence was
checked by BLAST alignment against the non-redundant
sequence database and at lower stringency (E = 100)
against all available LGIC subunit sequences [33]. The
peptide was found to be unique to 5-HT3B receptor subu-
nit protein. The peptide was synthesised by Research
Genetics (Huntsville, AL).
Preparation of antigenic peptide for injection
The immunogenic peptide was coupled to keyhole limpet
haemocyanin (KLH) by standard methods [34]. Briefly, 1
ml of a 10 mg/ml solution of KLH in PBS (pH 6.0) was
mixed with 1 mg m-maleimidobenzoic acid (MBS) for 30
min. Coupled KLH-MBS was purified using a Sephadex G-
25 column equilibrated to pH 7.4. The peptide was
reduced with 0.2 M sodium borate for 10 min followed by
neutralisation with 1 M HCl. 5 mg of reduced peptide was
dissolved in the KLH-MBS solution and stirred for 1 h at
room temperature. The coupled peptide was stored at -
20°C until required. Two male, New Zealand White, rab-
bits were injected subcutaneously with 1 mg conjugated
peptide, mixed with Freund's complete adjuvant. At
monthly intervals, for three months, rabbits were given
booster injections with 1 mg of conjugated peptide mixed
Western blots of lysates from untransfected HEK293 cells and HEK293 cells expressing mouse 5-HT3A or 5-HT3B receptor subunits, or human 5-HT3B recep or ubunitsFig re 1
Western blots of lysates from untransfected HEK293 cells and HEK293 cells expressing mouse 5-HT3A or 5-
HT3B receptor subunits, or human 5-HT3B receptor subunits. Blotted membranes were hybridised with dilutions of 
6377 serum or purified pAb77 IgG fraction as the primary antibody. Data are typical of three or more independent experi-
ments. The arrow indicates the position of 5-HT3B receptor subunits. Western blots using lysates from mouse tissues and 
N1E-115 cells are shown on the right hand side.Page 4 of 8
(page number not for citation purposes)
BMC Neuroscience 2006, 7:27 http://www.biomedcentral.com/1471-2202/7/27
Page 5 of 8
(page number not for citation purposes)
Immunolabelling by pAb77 of 5-HT3A and 5-HT3B receptor subunits expressed in HEK293 cellsFigure 2
Immunolabelling by pAb77 of 5-HT3A and 5-HT3B receptor subunits expressed in HEK293 cells. Confocal images 
of HEK293 cells fixed with 4% paraformaldehyde probed with immune sera and visualised by indirect immunofluorescence 
(FITC). (a) transfection of h5-HT3B probed with pre-immune sera (1:1000); (b) transient transfection of h5-HT3B probed with 
pAb77 (1:1000); (c) transient transfection of h5-HT3B and m5-HT3A probed with pAb77 (1:1000); (d) permeabilised cells (both 
panels) transiently transfected with either (left panel) m5-HT3A subunit cDNA, and probed with pAb120 antibody (1:300) or 
(right panel) m5-HT3A and h5-HT3B cDNA and probed with pAb77. Scale bars represent 10 µM.
BMC Neuroscience 2006, 7:27 http://www.biomedcentral.com/1471-2202/7/27with Freund's incomplete adjuvant. A harvest bleed was
taken at week 9.
SDS PAGE and Western blotting
Lysates of HEK293 cells transiently or stably expressing 5-
HT3 receptor subunits, or N1E-115 cells, were prepared by
freezing as previously described [24,35]. For mouse tis-
sues, 200 mg tissue was macerated with a needle in 0.5 ml
of extraction buffer containing 200 mM Tris-HCl pH 8.0,
250 mM NaCl, 25 mM EDTA and 0.5% SDS. The solution
was incubated at 50°C for 30 min and centrifuged at 4°C
for 5 min at 14 000 g. Samples of the supernatant were
mixed with an equal volume of electrophoresis sample
buffer (2% SDS, 100 mM dithiothreitol, 60 mM Tris-HCl
pH 6.8, 0.05% bromophenol blue) and heated at 95°C
for 5 min. They were then centrifuged at 21 000 g for 5
min and 15 µl loaded per lane on SDS-polyacrylamide
gels (10% – 12%) using the Mini-Protean 3 system (Bio-
Rad). Semi-dry electrophoretic transfer was used to elec-
troblot the separated proteins onto Hybond-ECL
nitrocellulose membranes (Amersham-Pharmacia) at 200
mA for 60–90 min (Biometra, Germany). Membranes
were stained using Ponceau S for 5 min to verify complete
transfer of proteins from the gel. The membranes were
incubated in PBS with 5% dried milk powder (Marvel) for
1 h to block non-specific binding sites and then incubated
in primary antibody solution in PBS/milk for 1 h with
continuous agitation at room temperature. Membranes
were washed four times with PBS and then incubated with
secondary antibody (a 1:2000 dilution in PBS/milk of
goat anti-rabbit antibody linked with horseradish peroxi-
dase, Sigma, MO). Labelling was visualised using the
ECL+ chemiluminescence system (Amersham-Pharma-
cia). For some blots, Tween 20 was added to the PBS solu-
tions at 0.05% to reduce background labelling.
Chemiluminescence was recorded by 10–360 s exposures
of Hyperfilm-ECL developed using an automatic film
developer (X-Omat; Kodak, US).
Purification of IgG fraction from immunoreactive serum
In order to decrease non-specific staining seen with the
crude serum from rabbit 6377, an immunoglobulin frac-
tion was affinity purified using a Protein A column. An
ImmunoPure Immobilised Protein A column (Pierce,
Rockford, IL) was equilibrated with 5 ml Binding Buffer
(Pierce). 1 ml of the 6377 final bleed serum was diluted
with 1 ml Binding Buffer and added to the column. 10
volumes of Binding Buffer were added to the column and
binding was monitored by measuring the absorbance at
280 nm of 1 ml fractions of the flow-through. 5 ml Elu-
tion Buffer was added to the column and the eluate con-
taining the IgG was collected. The eluate was concentrated
using a Centriprep-10 column (Millipore) following the
manufacturer's instructions to give a final volume of 700
µl (in 1 M Tris-HCl pH 8.0). The purified polyclonal anti-
body is referred to here as 'pAb77'.
Immunocytochemical visualisation of 5-HT3 receptors
HEK293 cells were grown on 22 mm glass cover slips and
washed three times with Tris-buffered saline (TBS: 0.1 M
Tris-HCl pH 7.4, 0.9% NaCl) fixed using 4% paraformal-
dehyde and then incubated in the appropriate dilution of
pAb77 antibody (1:100–1:2000) for 1 h at room temper-
ature. After three further washes with TBS, biotinylated
anti-rabbit IgG (Vector, CA) was added at 1:200 in TBS
and the cover slips incubated for 1 h at room temperature
and washed as before. Fluorescein isothiocyanate avidin
D (Vector) was added at a dilution of 1:200 in TBS with
Model of the 5-HT3B receptor subunit extracellular domainFigure 3
Model of the 5-HT3B receptor subunit extracellular 
domain. based on the structure of the nicotinic acetylcho-
line receptor, showing the location of peptides correspond-
ing to those used as immunogens for pAb77 (yellow) and 
AP86/3 (red).Page 6 of 8
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above. The cover slips were mounted in Vectashield
mounting medium (Vector) and immunofluorescence
observed using a Nikon epifluorescence microscope. Pho-
tomicrographs were taken using constant exposure times
of 50 s on Fuji RealA colour film (ASA 400) using a Nikon
camera attached to the microscope. Negatives were
printed by AM Photographic (Cambridge, UK) with image
brightness equalised to that of the negatives. Confocal
images were obtained for some preparations (BioRad-
MRC600).
Immunohistochemical visualisation of 5-HT3 receptors
Immunohistochemistry on tissue sections from rat brain
was performed using standard immunofluorescence and
immunoperoxidase procedures [27]. All procedures were
performed at room temperature unless otherwise stated.
Male Wistar rats (200–250 g) were deeply anaesthetized
and transcardially perfused with 100 ml 0.9% saline fol-
lowed by 400 ml 4% paraformaldehyde in 0.1 M phos-
phate buffer. Brains were removed, postfixed for 2 h and
cryoprotected overnight in 15% sucrose in 0.1 M phos-
phate buffer. Cryostat slide-mounted sections (15 µm), or
free floating sections cut on a Vibratome (40 µm), were
incubated for 1 h in 10% normal goat serum followed by
incubation with either crude 6377 serum (1:500–
1:10,000) or purified pAb77 IgG (1:500-1:500) in phos-
phate buffered saline (PBS) containing 0.2% Triton X-
100.
For immunofluorescence, sections were incubated for 48
h in primary antibody then washed in PBS and incubated
with tetramethylrhodamine-labelled donkey anti-rabbit
IgG (1:200) for 3 h. Sections were washed and mounted
in PBS:glycerol (1:3) containing 2.5% 1,4-diazobicyclo
(2,2,2)- octane to reduce fading. Sections for the immu-
noperoxidase procedure were incubated for 48 h in pri-
mary antibody and 2 h in biotinylated goat anti-rabbit
antiserum (1:400) followed by 2 h in avidin-biotin com-
plex (ABC, Vectastain Kit, Vector Laboratories). Immuno-
reactivity was detected using the nickel-intensified
diaminobenzadine method.
Abbreviations
5-HT: 5-hydroxytryptamine; CNS: central nervous system;
HEK: human embryonic kidney; KLH: keyhole limpet
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Immunohistochemical labelling of rat hippocampus with pAb77Figure 4
Immunohistochemical labelling of rat hippocampus with pAb77. (A). Typical results from immunoperoxidase-linked 
visualisation of pAb77 (1:5000) binding to rat hippocampal cryostat sections. Note the strong labelling of certain cells in the 
pyramidal cell layer (P). Scale bar represents 50 µM. (B) Schematic drawing of a coronal section of rat hippocampus. P = 
pyramidal layer, M = molecular layer.Page 7 of 8
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